biostudies-literatureCamp FANational Institutes of Health/National Cancer InstituteCancer Center Support GrantNCI NIH HHSMen for the Cure and the Department of Immunology and Microbiology at CU|AMC4397https://www.ebi.ac.uk/biostudies/studies/S-EPMC9496737biostudies-literatureUnknown14(18)Antigenic differences formed by alterations in gene expression and alternative splicing are predicted in breast cancer cells undergoing epithelial to mesenchymal transition (EMT) and the reverse plasticity known as MET. How these antigenic differences impact immune interactions and the degree to which they can be exploited to enhance immune responses against mesenchymal cells is not fully understood. We utilized a master microRNA regulator of EMT to alter mesenchymal-like EO771 mammary carcinoma cells to a more epithelial phenotype. A computational approach was used to identify neoantigens derived from the resultant differentially expressed somatic variants (SNV) and alternative splicing events (neojunctions). Using whole cell vaccines and peptide-based vaccines, we find superior cytotoxicCancersAntigens Expressed by Breast Cancer Cells Undergoing EMT Stimulate Cytotoxic CD8⁺ T Cell Immunity.PMC9496737T32 CA190216F32 CA239436P30 CA046934CA226879P30CA046934CA226879-04R01 CA226879Brunetti TMCamp FARicher JKSreekanth VKedl RMSlansky JEHay ZLZChristenson JLCostello JCWilliams MMfalseAntigens Expressed by Breast Cancer Cells Undergoing EMT Stimulate Cytotoxic CD8⁺ T Cell Immunity.Antigenic differences formed by alterations in gene expression and alternative splicing are predicted in breast cancer cells undergoing epithelial to mesenchymal transition (EMT) and the reverse plasticity known as MET. How these antigenic differences impact immune interactions and the degree to which they can be exploited to enhance immune responses against mesenchymal cells is not fully understood. We utilized a master microRNA regulator of EMT to alter mesenchymal-like EO771 mammary carcinoma cells to a more epithelial phenotype. A computational approach was used to identify neoantigens derived from the resultant differentially expressed somatic variants (SNV) and alternative splicing events (neojunctions). Using whole cell vaccines and peptide-based vaccines, we find superior cytotoxic2022-01-01T00:00:00Z2022 Sep2026-06-20T03:24:34.655Z2025-02-19T00:44:08.172ZS-EPMC94967373613955810.3390/cancers14184397